{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:53:27Z","timestamp":1780959207477,"version":"3.54.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To examine the efficacy and safety of dupilumab treatment in moderate-to-severe atopic dermatitis (AD) patients with comorbid allergic rhinitis (AR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 26 patients received subcutaneous dupilumab every 2 weeks and were followed up for 16 weeks. The efficacy assessment was evaluated based on clinical parameters every 4 weeks, including the Eczema Area and Severity Index (EASI), Pruritus Numeric Rating Scale (P-NRS), Severity Index (EASI), and Dermatology Life Quality Scale (DLQI) for the severity of AD symptoms, and the total nasal symptom scores (TNSS), visual analogue scale (VAS) and Mini Rhino-conjunctivitis Quality of Life Questionnaire (MiniRQLQ) for the severity of AR symptoms. The serum total immunoglobulin E (IgE) and eosinophil levels were collected at baseline and 16 weeks after dupilumab treatment. Treatment-emergent adverse events (TEAEs) ware conducted to evaluate the safety profile of dupilumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Dupilumab treatment resulted in a significant improvement in AD symptoms after 16 weeks as demonstrated by reduced EASI, NRS, DLQI, and ADCT scores. In addition, dupilumab treatment had a significant improvement in AR symptoms based on reduced TNSS, VAS and MiniRQLQ scores. After 16 weeks of dupilumab treatment, the blood eosinophil count, eosinophil percentage, and total serum IgE levels were significantly decreased when compared with the baseline values (<jats:italic>P<\/jats:italic> &amp;lt; 0.01 both). During the treatment period, the incidence of TEAEs was 13.77% (<jats:italic>n<\/jats:italic> = 8). The most commonly reported TEAEs were injection-site reactions (<jats:italic>n<\/jats:italic> = 13, 60.25%),<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Dupilumab treatment resulted in clinically relevant improvements in symptoms of AD and AR and had an acceptable safety profile.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1556769","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:27:03Z","timestamp":1744781223000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of dupilumab in patients with moderate-to-severe atopic dermatitis and comorbid allergic rhinitis"],"prefix":"10.3389","volume":"12","author":[{"given":"Tengfei","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangmei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/all.14318","article-title":"Type 2 immunity in the skin and lungs.","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy."},{"key":"B2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41572-020-00227-0","article-title":"Allergic rhinitis.","volume":"6","author":"Bousquet","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis.","volume":"384","author":"St\u00e4nder","year":"2021","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.anai.2017.10.037","article-title":"The atopic march: critical evidence and clinical relevance.","volume":"120","author":"Hill","year":"2018","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2500\/aap.2012.33.3569","article-title":"Epidemiology of atopic dermatitis: a review.","volume":"33","author":"DaVeiga","year":"2012","journal-title":"Allergy Asthma Proc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/pde.12867","article-title":"Study of the atopic march: development of atopic comorbidities.","volume":"33","author":"Schneider","year":"2016","journal-title":"Pediatr Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jaad.2022.01.009","article-title":"American academy of dermatology guidelines: awareness of comorbidities associated with atopic dermatitis in adults.","volume":"86","author":"Davis","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.4168\/aair.2018.10.4.300","article-title":"Chinese society of allergy guidelines for diagnosis and treatment of allergic rhinitis.","volume":"10","author":"Cheng","year":"2018","journal-title":"Allergy Asthma Immunol Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1111\/all.14586","article-title":"Advances and novel developments in allergic rhinitis.","volume":"75","author":"Meng","year":"2020","journal-title":"Allergy."},{"key":"B11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.anai.2018.07.042","article-title":"Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults.","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jdermsci.2018.01.016","article-title":"Dupilumab treatment in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.","volume":"90","author":"Wang","year":"2018","journal-title":"J Dermatol Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: a review of its use in the treatment of atopic dermatitis.","volume":"78","author":"Gooderham","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.2147\/JAA.S318892","article-title":"Short-term subcutaneous allergy immunotherapy and dupilumab are well tolerated in allergic rhinitis: a randomized trial.","volume":"14","author":"Corren","year":"2021","journal-title":"J Asthma Allergy."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1016\/s0091-6749(99)70054-0","article-title":"Update on therapy of atopic dermatitis.","volume":"104","author":"Hanifin","year":"1999","journal-title":"J Allergy Clin Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.jaci.2017.03.050","article-title":"Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision.","volume":"140","author":"Bro\u017cek","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial.","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","article-title":"Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension Trial (LIBERTY AD PED-OLE).","volume":"23","author":"Blauvelt","year":"2022","journal-title":"Am J Clin Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.anai.2021.02.026","article-title":"Rhinitis prevalence and association with atopic dermatitis: a systematic review and meta-analysis.","volume":"127","author":"Knudgaard","year":"2021","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/jdv.18919","article-title":"Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge-proven food allergy: a systematic review and meta-analysis.","volume":"37","author":"Christensen","year":"2023","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jaad.2020.02.055","article-title":"Prevalence of asthma in patients with atopic dermatitis: a systematic review and meta-analysis.","volume":"84","author":"Ravnborg","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers.","volume":"137","author":"Tomassen","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.jaci.2012.05.052","article-title":"Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-\u03b3 and IL-4.","volume":"130","author":"Soyka","year":"2012","journal-title":"J Allergy Clin Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11882-010-0096-0","article-title":"Rhinosinusitis and asthma: a link for asthma severity.","volume":"10","author":"Bachert","year":"2010","journal-title":"Curr Allergy Asthma Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes.","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation.","volume":"75","author":"Le Floc\u2019h","year":"2020","journal-title":"Allergy."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab.","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy."},{"key":"B29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis.","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e17520","DOI":"10.1371\/journal.pone.0017520","article-title":"Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010.","volume":"6","author":"Rehal","year":"2011","journal-title":"PLoS One."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study.","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/all.15653","article-title":"Dupilumab reduces symptom burden in allergic rhinitis and suppresses allergen-specific IgE production.","volume":"78","author":"Campion","year":"2023","journal-title":"Allergy."},{"key":"B35","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1398-9995.2004.00550.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: solar.","volume":"59","author":"Vignola","year":"2004","journal-title":"Allergy."},{"key":"B36","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jaci.2022.08.026","article-title":"Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events.","volume":"151","author":"Geba","year":"2023","journal-title":"J Allergy Clin Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases.","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jaci.2017.11.051","article-title":"Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma.","volume":"142","author":"Weinstein","year":"2018","journal-title":"J Allergy Clin Immunol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1556769\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:27:03Z","timestamp":1744781223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1556769\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":38,"alternative-id":["10.3389\/fmed.2025.1556769"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1556769","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"article-number":"1556769"}}